AUSTRALIAN medical devices company Uscom says it has manufactured its first Uscom BP+ blood pressure analysis device at its head office in Circular Quay, Sydney.
The Uscom BP+ is a high fidelity, central blood pressure and pulse pressure wave analysis technology based on patent protected suprasystolic oscillometric blood pressure measurements specialised for advanced assessment of hypertension and heart failure.
Uscom acquired the BP+ technology along with Pulsecor assets in June 2013. The effort to integrate the company has resulted in this first production run of 180 BP+ units. The BP+ has both CE Mark and FDA 510K status, and with its arrival, Uscom now manufactures 2 cardiovascular devices at its Australian centre of operations - the USCOM 1A and the BP+.
The company has been appointing new distributors for the BP+ device, and developing new marketing collateral. Seven new distributors have been appointed covering the UK and China, and they are preparing to sell the BP+ as soon as the relevant regional regulatory approvals permit.